IMR Press / EJGO / Volume 33 / Issue 6 / pii/1631087799906-451391240

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research
Octreotide is the favorable alternative for cisplatin resistance reversal of ovarian cancer in vitro and in nude mice in vivo
Show Less
1 Department of Obstetrics and Gynecology, Zhongda Hospital, Southeast University, Nanjing (China)
Eur. J. Gynaecol. Oncol. 2012, 33(6), 584–590;
Published: 10 December 2012

This study aimed to observe the effects of octreotide (OCT) on cisplatin resistance reversal of cancer cells in vitro and in nude mice in vivo. MTT method and flow cytometry were used to investigate the effect of cisplatin, OCT or the combination of these two compounds on the proliferation and apoptosis of SKOV3-DDP cells. The size and weight of xenograft tumors from the nude mice model were measured. Real-time PCR was used to detect the mRNA expression of SSTR2, MDR1, MRP2, GST-π and EGFR in SKOV3/DDP cells following the different treatment. At the concentration of 2.5-20 g/mL, OCT significantly reduced IC50 (p < 0.05) and promoted apoptosis (p < 0.05) of SKOV3-DDP cells’ response to cisplatin. Unchanged expression was found in SSTR2 on the SKOV3/DDP cell in vitro after OCT treatment, but increased expression in vivo (p < 0.05). OCT increased GST-π expression (p < 0.05) and reduced MRP2 and EGFR expression (p < 0.05) in a dose-dependent manner. The similar results were obtained in mice in vivo experiment, except the reduced expression of GST-π. It is suggested that OCT could inhibit ovarian cancer proliferation and promote apoptosis, via the cell surface SSTR2, and reverse cisplatin resistance through inhibition of MRP2, EGFR, and even GST-π expressions.
Epithelial ovarian cancer
Resistance reversal
Back to top